Investor Overview

Investor Overview

Corporate Profile

Y-mAbs Therapeutics Inc. (Y-mAbs) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center. Its mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs. Y-mAbs also seeks to advance and expand its product pipeline into certain adult cancer indications and to leverage its extensive drug development capabilities and platform technology towards the creation of new types of bispecific antibodies.

Stock Quote

Minimum 15 minutes delayed. Source:

News Releases

Oct 01, 2024

Y-mAbs to Participate in Upcoming Investor Conferences in October

Sep 06, 2024

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Sep 03, 2024

Y-mAbs to Participate in Upcoming Investor Conferences in September